Vanguard Group Inc Albireo Pharma, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$18.01 - $23.78 $559,246 - $738,416	31,052 Added 3.38%	948,532 $20.5 Million
Q3 2022 Nov 14, 2022	SELL	$16.32 - $26.37 $1.25 Million - $2.02 Million	-76,490 Reduced 7.7%	917,480 $17.8 Million
Q2 2022 Aug 12, 2022	BUY	$18.54 - $37.29 $302,294 - $608,013	16,305 Added 1.67%	993,970 $19.7 Million
Q1 2022 May 13, 2022	BUY	$23.94 - $33.74 $1.01 Million - $1.43 Million	42,235 Added 4.52%	977,665 $29.2 Million
Q4 2021 Feb 14, 2022	SELL	$21.19 - $31.29 $338,531 - $499,889	-15,976 Reduced 1.68%	935,430 $21.8 Million

Q3 2021 Nov 12, 2021	BUY	$27.36 - $35.98 $738,966 - $971,783	27,009 Added 2.92%	951,406 $29.7 Million
Q2 2021 Aug 13, 2021	BUY	$28.9 - $36.87 $26.7 Million - $34.1 Million	924,397 New	924,397 $32.5 Million

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.